

TABLE OF CONTENTS

June 28, 2010

No. 2194

BUSINESS

- 1 Merck Serono to Launch More Than 6 Products in 2012 Onward
- 2 Takeda Launches 3 New Products Aiming at Combined Sales of ¥10 Bil. in 1st Year
 - Takeda Enters Oncology Field in Earnest with Vectibix, Vercade
- 3 Daiichi Sankyo to Develop Vaccine Business in Japan and Emerging Markets
- 3 Bayer to Strengthen Marketing Structure in General Medicine
- 4 MTPC Presents Business Improvement Plans to *Koroshō*
 - *Koroshō* to Monitor Progression of Improvements
- 5 Ensure Value-Matched Sales of Drugs: New JPMA Marketing Committee Chairman
 - Distribution Business Practice Being Improved
- 6 **BUSINESSNEWSINBRIEF**
 - Kowa Licenses Livalo to Abbott in Australia, New Zealand
 - Asahi Kasei Pharma Licenses Zoledronic Acid from Novartis
 - Takeda Terminates Collaboration with CanBas for CBP501
 - GSK, Yoshitomi to Terminate Copromotion of Paxil in July
 - Pfizer Creates Rare Disease Research Unit
 - Astellas' Brazilian Affiliate Starts Operation
 - ACRONET Invests in Chinese CRO NANDACRO
 - FTC Warns Nakazawa Ujike for Possible Anti-Monopoly Act Infringements
 - MCI to Launch New Detailing Tool Using iPad in July
- 8 **NEWPRODUCTS**
 - Novo Launches Japan's 1st GLP-1 Agonist Victoza
 - Hisamitsu, Kyowa Kirin Launch Fentos Tape for Relief of Cancer Pain
- 9 **TOPICS**
 - Otsuka Gives Apple's iPad to Every MR

GENERICS

- 9 Speed Is Key to Success of sanofi-aventis Nichi-Iko: Dr Chocat
 - Greater Price Gaps Should Be Allowed between Original Products and Generics: Dr Chocat
- 10 Research-Driven Companies Also to Be Blamed for Jam of Generics: Mr Sawai
 - Detailing as Heavy as for Original Drugs Not Necessary for Generics: Mr Masuhara
 - Physicians Remain Concerned about Generics of Anticancer Agents: Dr Sasaki
 - Nearly 80% of Doctors Have Heard Negative Views on Generics from MRs, MSs: Mr Urushibata
- 12 **Commentary**
 - How Will Generics-Only Companies Will Compete with Major New Entrants?
- 11 **Statistics**
 - Ethical Drugs' Sales Up 10.2% in April: Crecon

REGULATORY

- 14 FPMAJ Subcommittee Calls For Full-Scale Introduction of Premium for Development of New Drugs
 - Foreign-Affiliated Companies Receive Premium for More Products than Domestic Companies
 - Cost of 8 Products Calculated Using Higher-Than-Standard Operating Profit Rates
 - <2.5-Fold Price Differences between Generic Brands in Most Cases
- 16 2 Sets of GLs for Development of Vaccines Issued
- 16 **REGULATORYNEWSINBRIEF**
 - Continued Treatment with Strattera Now Permitted after 18th Anniversary
 - LTT Bio-Pharma's IPF Drug Midismase Obtains Orphan Status
 - Additional Indication Approved for Actemra in Europe: Roche
 - *Koroshō* to Increase Transparency of NDA Review Process: Mr Nagatsuma
 - FDA Orders Eisai, Sepracor to Stop Using Some Promotional Materials

R&D

- 18 CMIC Decides to Develop Sodium Phenylbutyrate
 - CMIC Believes in Profitability of the Drug
- 19 **ASCO 2010 in Chicago (2)**
 - Interim Analysis Confirms Safety of Tykerb in PIII for Stomach Cancer
 - Cabazitaxel Increases OS in Prostate Cancer Patients
 - Sutent Fails to Show Efficacy for Breast Cancer in All 4 of the PIII Trials
 - Maintenance Therapy with Rituximab Halves Risk of Recurrent Lymphoma
 - Denosumab Effective for Bone Metastasis Following Prostate Cancer
 - Zometa Improves OS in Patients with *De Novo* Multiple Myeloma
 - Pfizer's Crizotinib to Contribute to Personalized Treatment of NSCLC
 - Sprycel Effective in First-Line Therapy for CML-CP
 - 4-Year Follow-up Data from Sprycel-Treated Patients Announced
- 21 **R&DNEWSINBRIEF**
 - Meiji Seika Begins PIIa Study for Fibromyalgia with Mirtazapine
 - SymBio Licenses Lupuzor from Cephalon
 - JPMA Releases List of Unapproved Drugs/Indications without Development Sponsor
 - Afinitor Extends PFS in Advanced pNET Patients in PIII: Novartis
 - Kansai Bio-Promotion Allies with Flanders Bio

MEDICAL FACILITIES & NURSING CARE

- 22 NBI, Astellas Disagree With Meta-Analysis on Safety of Telmisartan
- 23 **MEDICALFACILITIES&NURSINGCARENEWSINBRIEF**
 - NCCHD Considers Gene Therapy for Chronic Granuloma
 - *Koroshō*'s Panel Begins Discussions for Early Diagnosis of COPD